4:41 PM
 | 
Jul 07, 2014
 |  BC Extra  |  Company News

EC approves GSK's Mekinist as monotherapy

The European Commission approved Mekinist trametinib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) as monotherapy to treat unresectable or metastatic melanoma in adults with a BRAF V600 mutation. The pharma said it is finalizing launch plans, including timing....

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >